From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 1.94
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Dpp4) extracellular region (Dpp4) cell adhesion (Dpp4)
Golgi apparatus (Dpp4) endoplasmic reticulum (Dpp4) plasma membrane (Dpp4)
Anatomy Link Frequency
beta cell 1
Dpp4 (Mus musculus)
Pain Link Frequency Relevance Heat
tolerance 16 90.38 High High
Neuropeptide 3 64.24 Quite High
substance P 2 62.64 Quite High
agonist 41 60.08 Quite High
chemokine 2 59.60 Quite High
cva 2 40.56 Quite Low
pruritus 4 26.56 Quite Low
Inflammation 10 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 293 96.64 Very High Very High Very High
Hypoglycemia 88 95.76 Very High Very High Very High
Impaired Glucose Tolerance 14 90.38 High High
Thrombocytopenia 2 87.68 High High
Anaemia 2 86.24 High High
Alopecia 2 83.92 Quite High
Hyperinsulinism 4 80.40 Quite High
Targeted Disruption 3 77.32 Quite High
Weight Loss 18 70.32 Quite High
Obesity 28 64.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As individuals progress from normal glucose tolerance to IGT to T2DM, stimulated GLP-1 levels decline89,90 (Figure 7), and there is beta cell resistance to the glucose-dependent stimulatory effect of both GLP-1 and GIP on insulin secretion.91 In T2DM the contribution of incretin hormones to the insulin response has been estimated to be reduced to about 36% in T2DM subjects.86,92 From the therapeutic standpoint, one can increase circulating GLP-1 levels by administering a GLP-1 analog that is resistant to DPP-4 degradation or by giving a DPP-4 inhibitor.7,93,94
DPP-4 Binding (giving) of in beta cell associated with diabetes mellitus, tolerance and impaired glucose tolerance
1) Confidence 0.14 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.58 Pain Relevance 0.05
Selectivity of alogliptin for DPP-4 inhibition is defined as a > 10,000 greater affinity for the DPP-4 enzyme than for competing DPP enzymes, such as DPP-2, 8, and 9.
DPP-4 Binding (affinity) of
2) Confidence 0.12 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.88 Pain Relevance 0.09
DPP-4 activity is reduced by almost 100% within 15 to 30 minutes of oral administration of the DPP-4 inhibitors sitagliptin or vildagliptin, producing a 2-fold increase in mean active GLP-1 levels (to 15 to 25 pmol/L), with a duration of inhibition in excess of 16 hours because of initial rapid binding to DPP-4, followed by a slow phase of tight binding,92 so that effects persist for 24 hours after administration of a single dose of sitagliptin93 and vildagliptin.94 DPP-4 inhibition increases GLP-1 and GIP levels by 2- to 3-fold, while reducing glucagon,92 although the magnitude of the rise in GLP-1 is dependent on the type of nutrient ingested.
DPP-4 Binding (binding) of
3) Confidence 0.12 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731024 Disease Relevance 0.48 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools